Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2012

View Archived Issues

Adenovir Pharma completes phase I study of APD-209

Novel compound demonstrates potential for stabilizing alpha-synuclein

KBP Biosciences discloses novel mineralocorticoid receptor antagonists

Novel gene therapy for Huntington's disease presented by Genzyme

Copernicus designs noninvasive method for gene therapy delivery into the brain

New OGA inhibitors prepared by Alectos Therapeutics and Merck & Co.

Team at Harvard College patents new TNF-alpha production inhibitors

Incyte presents novel PI3Kdelta inhibitors

Merck & Co. synthesizes new HCV NS5A inhibitors

European Commission awards grant to support development of NI-0501

Jazz Pharmaceuticals closes sale of women's health business

Scientists at Wellstat Therapeutics disclose novel URAT1 inhibitors

Theravance and Merck & Co. to collaborate in cardiovascular disease

Resverlogix begins phase II trial of RVX-208 in patients with prediabetes

RedHill Biopharma reports data from three preclinical studies

Researchers identify novel peptide biomarker to predict breast cancer bone metastasis

Kite Pharma partners with NCI

A.P. Pharma confirms FDA action date for APF-530 resubmission

BioLineRx completes preclinical development for anti-HCV agent

ArQule and Daiichi Sankyo enter SPA agreement with FDA

MAP Pharmaceuticals resubmits Levadex NDA to the FDA

Ajinomoto files for approval of combination treatment for hypertension in Japan

DiaMedica reports preclinical results from DM-199 study

FDA recommends Gattex in adults with short bowel syndrome

AB Science seeking European approval for masitinib in treatment of pancreatic cancer

Novartis files additional application for Xolair in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...